Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies

Autor(es)

Oliveira, Giuliana S. ^[1] ; Oliveira, Maria Leonor S. ^[1] ; Miyaji, Eliane N. ^[1] ; Rodrigues, Tasson C. ^[1]

Afiliação do(s) autor(es)

^[1] Inst Butantan, Lab Bacteriol, BR-05503900 Sao Paulo, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: VACCINES; v. 9, n. 11 NOV 2021.
• Citações Web of Science: 0

Resumo

The importance of Streptococcus pneumoniae has been well established. These bacteria can colonize infants and adults without symptoms, but in some cases can spread, invade other tissues and cause disease with high morbidity and mortality. The development of pneumococcal conjugate vaccines (PCV) caused an enormous impact in invasive pneumococcal disease and protected unvaccinated people by herd effect. However, serotype replacement is a well-known phenomenon that has occurred after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) and has also been reported for other PCVs. Therefore, it is possible that serotype replacement will continue to occur even with higher valence formulations, but the development of serotype-independent vaccines might overcome this problem. Alternative vaccines are under development in order to improve cost effectiveness, either using proteins or the pneumococcal whole cell. These approaches can be used as a stand-alone strategy or together with polysaccharide vaccines. Looking ahead, the next generation of pneumococcal vaccines can be impacted by the new technologies recently approved for human use, such as mRNA vaccines and viral vectors. In this paper, we will review the advantages and disadvantages of the addition of new polysaccharides in the current PCVs, mainly for low- and middle-income countries, and we will also address future perspectives. (AU)

• Processo FAPESP: 17/26090-7 - Formulação de vacina pulmonar nanoparticulada baseada em lipossomos contendo antígenos protéicos de Streptococcus pneumoniae
• Beneficiário: Tasson da Costa Rodrigues
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 18/25165-6 - Papel de anticorpos contra variantes de PspA e PspC na proteção contra Streptococcus pneumoniae
• Beneficiário: Eliane Namie Miyaji
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 19/15961-2 - Caracterização da resposta imune a vacinas contra Streptococcus pneumoniae em diferentes condições de resposta inflamatória aguda
• Beneficiário: Giuliana Stephani de Oliveira
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 19/06190-2 - Caracterização da resposta imune a vacinas contra Streptococcus pneumoniae em camundongos com alta susceptibilidade a infecção.
• Beneficiário: Maria Leonor Sarno de Oliveira
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 21/04996-0 - Interação de Streptococcus pneumoniae, vesículas extracelulares e nanopartículas com células em modelos de epitélio do trato respiratório
• Beneficiário: Eliane Namie Miyaji
• Modalidade de apoio: Auxílio à Pesquisa - Regular